Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Earnings for Lexicon Pharmaceuticals, Inc. (LXRX)
Earnings in 2023 (TTM): $-177,119,000
According to Lexicon Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-177,119,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Lexicon Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-177,119,000 | $-177,119,000 |
| 2022 | $-101,944,000 | $-103,128,000 |
| 2021 | $-87,758,000 | $-88,268,000 |
| 2020 | $-58,574,000 | $-70,184,000 |
| 2019 | $124.12 M | $130.13 M |
| 2018 | $-120,548,000 | $-120,548,000 |
| 2017 | $-141,711,000 | $-129,050,000 |
| 2016 | $-141,429,000 | $-141,429,000 |
| 2015 | $-4,682,000 | $-4,682,000 |
| 2014 | $-100,364,000 | $-100,294,000 |
| 2013 | $-104,126,000 | $-104,126,000 |
| 2012 | $-110,211,000 | $-110,211,000 |
| 2011 | $-116,215,000 | $-116,215,000 |
| 2010 | $-101,801,000 | $-101,775,000 |
| 2009 | $-93,419,000 | $-82,780,000 |
| 2008 | $-96,884,000 | $-76,860,000 |
| 2007 | $-71,233,000 | $-58,794,000 |
| 2006 | $54.43 M | $-54,311,000 |
| 2005 | $39.2 M | $-36,315,000 |
| 2004 | $-46,150,000 | $-47,172,000 |
| 2003 | $ | $-64,198,000 |
| 2002 | $ | $-59,670,000 |
| 2001 | $ | $-35,172,000 |
| 2000 | $ | $-25,994,080 |
| 1999 | $ | $-12,500,000 |